Carmell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021
Market Capitalization	42	88	196	190
Market Cap Growth	-	-55.14%	3.09%	-
Enterprise Value	42	87	200	200
PE Ratio	-5.45	-5.45	-20.41	-28.02
PB Ratio	1.72	3.55	-5.19	-6.43
P/FCF Ratio	-10.50	-10.50	-57.06	-160.61
P/OCF Ratio	-10.53	-10.53	-57.18	-161.60
EV/EBITDA Ratio	-6.03	-6.03	-28.11	-36.20
EV/EBIT Ratio	-5.97	-5.97	-27.18	-34.68
EV/FCF Ratio	-10.40	-10.40	-58.11	-168.78
Debt / Equity Ratio	0.09	0.09	-0.10	-0.33
Debt / EBITDA Ratio	-0.15	-0.15	-0.53	-1.75
Debt / FCF Ratio	-0.25	-0.25	-1.09	-8.18
Quick Ratio	0.08	0.08	0.02	0.00
Current Ratio	1.63	1.63	0.08	0.01
Interest Coverage	-17.09	-17.09	-4.31	-8.06
Return on Equity (ROE)	-1325.20%	-1325.20%	71.00%	80.00%
Return on Assets (ROA)	-38.10%	-38.10%	-8.20%	-17.20%
Return on Capital (ROIC)	-22.11%	-22.11%	16.17%	9.76%
Earnings Yield	-37.93%	-18.33%	-4.90%	-3.57%
FCF Yield	-19.72%	-9.53%	-1.75%	-0.62%
Buyback Yield / Dilution	-527.34%	-527.34%	92.41%	-
Total Shareholder Return	-527.34%	-527.34%	92.41%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).